

Amaxa™ HT Nucleofector™ basic protocol for human stem cells

Cell description

For human stem cells; e.g. H1, H7, H14, HS306 ; pluripotent cells, adherent.

Note

This basic protocol describes how to easily define optimal Nucleofection™ conditions for different human stem cells (e.g. H1, H7, H14, HS306). We recommend first testing a set of pre-selected Nucleofector™ programs together with two of our primary cell HT Nucleofector™ kits:

- P3 primary cell HT Nucleofector™ kit
- P4 primary cell HT Nucleofector™ kit

For subsequent experiments simply use the kit which yields the best results.

If you have questions regarding your human stem cell of interest, please contact our scientific support team for further help with the optimization.

Product description

Recommended kits

P3 primary cell HT Nucleofector™ kits

Cat. No.	V5SP-3002
Size (reactions)	2×384
P3 primary cell HT Nucleofector™ solution	22.5 ml
Supplement	5 ml
pmaxGFP™ vector (1 µg/µl in 10 mM Tris pH 8.0)	50 µg
384-well Nucleocuvette™ plate (s)	2

Cat. No.	V5SP-3010
Size (reactions)	10×384
P3 primary cell HT Nucleofector™ solution	90 ml
Supplement	20 ml
pmaxGFP™ vector (1 µg/µl in 10 mM Tris pH 8.0)	150 µg
384-well Nucleocuvette™ plate (s)	10

Recommended kits

P4 primary cell HT Nucleofector™ kits

Cat. No.	V5SP-4002
Size (reactions)	2×384
P4 primary cell HT Nucleofector™ solution	22.5 ml
Supplement	5 ml
pmaxGFP™ vector (1 µg/µl in 10 mM Tris pH 8.0)	50 µg
384-well Nucleocuvette™ plate (s)	2

Cat. No.	V5SP-4010
Size (reactions)	10×384
P4 primary cell HT Nucleofector™ solution	90 ml
Supplement	20 ml
pmaxGFP™ vector (1 µg/µl in 10 mM Tris pH 8.0)	150 µg
384-well Nucleocuvette™ plate (s)	10

Storage and stability

Store Nucleofector™ solution, supplement and pmaxGFP™ vector at 4°C. For long term storage pmaxGFP™ vector is ideally stored at -20°C. The expiry date is printed on the solution box. Once the Nucleofector™ supplement is added to the Nucleofector™ solution it is stable for three months at 4°C.

Note

HT Nucleofector™ solutions can only be used with conductive polymer cuvettes, i.e. in the HT Nucleofector™, the 96-well Shuttle™ device and in the 4D-Nucleofector™ system. They are not compatible with the Nucleofector™ II/2b device.

Optimization guidelines

The initial optimization experiment is comprised of 32 reactions: 7 different Nucleofector™ programs are tested in duplicate with 2 Nucleofector™ solutions plus 1 control. The program and HT Nucleofector™ solution which turned out to be the most appropriate Nucleofection™ condition should be used for all subsequent transfections.

	P3 primary cell Nucleofector™ solution		P4 primary cell Nucleofector™ solution	
	1	2	3	4
A	CA-137-AA	CA-137-AA	CA-137-AA	CA-137-AA
B	CB-150-AA	CB-150-AA	CB-150-AA	CB-150-AA
C	CD-118-AA	CD-118-AA	CD-118-AA	CD-118-AA
D	CE-118-AA	CE-118-AA	CE-118-AA	CE-118-AA
E	CM-113-AA	CM-113-AA	CM-113-AA	CM-113-AA
F	DC-100-AA	DC-100-AA	DC-100-AA	DC-100-AA
G	DN-100-AA	DN-100-AA	DN-100-AA	DN-100-AA
H	negative control (no program)	negative control (no program)	negative control (no program)	negative control (no program)

Required material

Note

Please make sure that the entire supplement is added to the Nucleofector™ solution.

- HT Nucleofector™ system
- Supplemented HT Nucleofector™ solution at room temperature prior to Nucleofection™
- Supplied 384-well Nucleocuvette™ plates
- Supplied pmaxGFP™ vector, stock solution 1 µg/µl

Note

Volume of substrate solution added to each sample should not exceed 10 % of the total reaction volume (2 µl for 20 µl reactions). For positive control using pmaxGFP™ vector, please dilute the stock solution to reach the appropriate working concentration.

- Substrate of interest, highly purified, preferably by using endotoxin free Kits; A260 : A280 ratio should be at least 1.8
- 384-well Nucleocuvette™ plates are best handled with an automated liquid handling system. If manual pipetting is required please use compatible tips: epT.I.P.S.™ (US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266) or Matrix TallTips™ (Matrix Technologies Corp., Cat. No. 7281). Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ wells without getting stuck
- 384-well culture plates or culture plates of your choice

- For detaching the cells: Accutase solution (PAA Laboratories, Cat. No. L11-007) or 0.05 or 0.25 % Trypsin/EDTA solution (Invitrogen, Cat. No. 253000-54 or 252000-56)
- Appropriate volume of culture medium
- Appropriate number of cells (2×10⁵ to 4×10⁵ cells per sample)

For culture with feeder cells:

- Pre-warm appropriate volume of culture media at 37°C (192 µl per sample); DMEM:F-12 (Lonza, Cat. No. 12-719F) supplemented with 15–20 % serum replacement (Invitrogen, Cat. No. 10828-028), 1–2 % nonessential amino acids (Lonza, Cat. No. 13-114E), 1–4 mM L-glutamine (Lonza, Cat. No. 17-605C), 0.1 mM 2-Mercaptoethanol (Invitrogen, Cat. No. 21985-023) and 4–8 ng/ml fibroblast growth factor-2 (Milipore, Cat. No. GF003AF-MG)
- Prepare a well plate coated with gelatine and inactivated feeder cells (one well per sample) 24 hours before Nucleofection™

For feeder-free culture:

- Pre-warm appropriate volume of culture media at 37°C (192 µl per sample; mTesSR™ 1 medium (StemCell Technologies, Cat. No. 05850)
- Prepare a well culture plate coated with Matrigel™ (BD Biosciences, Cat. No. 354277)

1. Pre Nucleofection™

Note

Transfection results may vary due to different culture conditions prior and post Nucleofection™.

Important considerations—single cell suspension

- We recommend transfecting the cells in single cell suspension. Nucleofection™ of clumps leads to lower transfection efficiency and less reproducibility (for details see reference 1)
- If single cell suspension passage is not established, please do some pre-experiments by testing Accutase (reference 2 and 3) and Trypsin (reference 4) for detachment. Cultivate the cells afterwards and analyze which method led to highest viability and lowest differentiation
- The use of apoptosis inhibitors like ROCK inhibitor (reference 5) and neurotrophins (reference 6) have been reported to increase viability of hES cells. Depending on hESC culture conditions, it might be advantageous to use ROCK inhibitor or neurotrophins to obtain higher viabilities cell culture recommendations

- 1.1 Replace media every day
- 1.2 Cells should be passaged 1–2 times per week with a sub-cultivation ratio of 1 : 3 to 1 : 10. You may use Collagenase, Dispase or another enzyme for this purpose

Detachment of stem cells

1.3 A. Harvest of stem cells cultured on feeder cells

There are three possibilities to remove feeder cells from your stem cell culture prior to Nucleofection™:

- If your stem cells are usually cultured on feeder cells, passage them once to Matrigel™ coated plates to remove the feeder cells (described in reference 2). Then proceed to step 1.3 B
- Cultivate the cells on feeder cells until the day of the experiment. Detach the stem cells with Collagenase. Dissociate the clumps with Accutase into a single cell suspension
- Cultivate the cells on feeder cells until the day of the experiment. Detach all cells with Accutase. Incubate the cells on an uncoated cell culture flask for 1 hour in a humidified 37°C/5% CO₂ incubator.
- The feeder cells will attach and the stem cells will stay in suspension. Harvest the cells in suspension

B. Harvest of feeder-free stem cell cultures

- Prior to Nucleofection™ detach the hES cells from the Matrigel™ plates by incubation with Accutase for 5 minutes at 37°C. Dissociate the cells into a single cell suspension by pipetting the suspension carefully up and down 4–6 times.
- Add medium to stop Accutase

- 2.4 Prepare cell culture plates by filling appropriate number of wells with desired volume of recommended culture media, e.g. 152 µl (see comments at the end of this chapter*) for one well of a 384-well plate coated with Matrigel™ or gelatine and feeder cells and pre-incubate/equilibrate plates in a humidified 37°C/5% CO₂ incubator
- 2.5 Pre-warm /equilibrate an aliquot of culture media to 37°C (40 µl per sample)
- 2.6 Prepare 0.4–1 µg plasmid DNA or 0.4–0.8 µg pmaxGFP™ vector
- 2.7 Harvest the cells (please see 1.3)
- 2.8 Count an aliquot of the detached cells and determine cell density
- 2.9 Centrifuge the required number of cells (2×10⁵ cells per sample) at 115×g for 3 minutes at room temperature
- 2.10 Resuspend the cell pellet carefully in 20 µl room temperature HT Nucleofector™ solution per sample

A: One or several substrates (DNAs or RNAs) in multiples

- Prepare mastermixes by dividing cell suspension according to number of substrates
- Add required amount of substrates to each aliquot (max. 2 µl per sample)
- Transfer 20 µl of mastermixes into the wells of the 384-well Nucleocuvette™ plates

B: Multiple substrates (e.g. library transfection)

- Pipette 20 µl of cell suspension into each well of a sterile U-bottom 384-well microtiter plate
- Add 2 µl substrates (maximum) to each well
- Transfer 20 µl of cells with substrates into the wells of the 384-well Nucleocuvette™ plates

2. Nucleofection™

One Nucleofection™ sample contains

- 2×10⁵ cells
- 0.4–1µg plasmid DNA (in 1–2 µl H₂O or TE) or 0.4–0.8 µg pmaxGFP™ vector
- 20 µl HT Nucleofector™ solution

Note

Human stem cells are quite sensitive to environmental conditions. Therefore please ensure you proceed with the Nucleofection™ steps as fast as possible.

- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ solution
- 2.2 Start HT Nucleofector™ software, verify device connection and upload experimental parameter file (refer to the HT Nucleofector™ manuals)
- 2.3 Select appropriate HT Nucleofector™ program. Please try all 7 Nucleofector™ programs (CA-137-AA, CB-150-AA, CD-118-AA, CE-118-AA, CM-113-AA, DC-100-AA and DN-100-AA) initially with both Nucleofector™ solutions to determine the most appropriate Nucleofection™ condition for your specific stem cell type

Note

It is advisable to pre-dispense each cell suspension into a sterile round-bottom 384-well plate or to pipet from a pipetting reservoir for multi-channel pipettes. Use a liquid handling system or at least a multi-channel pipette with suitable pipette tips. Leaving cells in HT Nucleofector™ solution for extended periods of time may lead to reduced transfection efficiency and viability. It is important to work as quickly as possible. Avoid air bubbles while pipetting.

- 2.11 Briefly shake the 384-well Nucleocuvette™ plate with an appropriate microtiter plate shaker to make sure the sample covers the bottom and sides of the wells without air bubbles. Alternatively thoroughly tap the 384-well Nucleocuvette™ plate
- 2.12 Place well Nucleocuvette™ plate with closed lid onto carousel of the plate handler. Well "A1" must be in upper left position
- 2.13 Start the HT Nucleofection™ process by clicking "Start" in the HT Nucleofector software (for details refer to HT Nucleofector™ manuals)

- 2.14 After run completion, carefully remove the well Nucleocuvette™ plate from the retainer
- 2.15 Resuspend cells with desired volume of pre-warmed media (maximum cuvette volume 60 µl). Mix cells by gently pipetting up and down two to three times. Recommendation for well plates: Resuspend cells in 40 µl of pre-warmed media
- 2.16 Plate desired amount of cells in culture system of your choice. Recommendation for well plates: Transfer 48 µl of resuspended cells to 152 µl pre-warmed media prepared in 384-well culture plates coated with Matrigel™ or gelatine and feeder cells
- 2.17 If post Nucleofection™ cell culture is done in BD Matrigel™ (BD Biosciences) coated well plates, centrifuge the culture plates loaded with cells at this point to guarantee proper attachment of the cells (70×g, 3 minutes, room temperature)

Notes

The Matrigel™ plates used for culturing of human stem cells should be fresh. Storage of these plates for more than 7 days leads to reduced attachment of the cells post Nucleofection™. The indicated plating cell numbers and volumes produce optimal Nucleofection™ results in most cases. However, you may wish to test an extended range of cell numbers depending on your specific needs.

3. Post Nucleofection™

- 3.1 Incubate the cells in a humidified 37°C/5% CO₂ incubator until analysis. Gene expression is often detectable after only 4–8 hours
- 3.2 As cells were plated at high density post Nucleofection™, a passage step 48 hours post Nucleofection™ using Collagenase or Dispase might be necessary

Note

The plating density post Nucleofection™ is a critical aspect for the viability of human stem cells. Our experience is that higher densities lead to better viability of the cells. Therefore we recommend plating human stem cells at densities from 4×10^5 to 6.5×10^5 cells per cm².

Additional information

Up-to-date list of all Nucleofector™ references

www.lonza.com/nucleofection-citations

Technical assistance and scientific support

USA/Canada

Tel 800 521 0390 (toll-free)

Fax 301 845 8338

scientific.support@lonza.com

Europe and Rest of World

Tel +49 221 99199 400

Fax +49 221 99199 499

scientific.support.eu@lonza.com

References

1. Nucleofection Mediates High-efficiency Stable gene Knockdown and Transgene Expression in Human Embryonic Stem Cells; Kristi A. Hohenstein et al. [2008]; Stem Cells First published online March 20, 2008; doi:10.1634/stemcells.2007-0857
2. Nucleofection of Human Embryonic Stem Cells; Henrike Siemen et al. [2005]; Stem Cells and Development: 14: 378-383
3. Efficient propagation of single cells acutase-dissociated human embryonic stem cells; Ruchi Bajpai. et al. [2008]; Molecular Reproduction and Development
4. Facilitated expansion of human embryonic stem cells by single cell enzymatic dissociation; Catharina Ellerström et al. [2007]; Stem Cells 25: 1690-1696
5. A ROCK inhibitor permits survival of dissociated human embryonic stem cells; Kiichi Watanabe et al. [2007]; Nature Biotechnology 25 (6): 681-686
6. Neutrophins mediate human embryonic stem cell survival; April D. Pyle et al. [2006]; Nature Biotechnology: 24 (3): 344-350
7. Efficient and Stable Transgene Expression in Human Embryonic Stem Cells Using Transposon-Mediated Gene Transfer; Andrew Wilber et al. [2007]; Stem Cell 25: 2919-2927
8. Efficient Transfection of Embryonic and adult stem cells; Uma Lakshminpathy et al. [2004]; Stem Cells: 22: 531-543

www.lonza.com

Lonza Cologne GmbH—50829 Cologne, Germany

Please note that the Amata™ Nucleofector™ technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector™ technology, comprising Nucleofection™ process, Nucleofector™ device, Nucleofector™ solutions, Nucleofector™ 96-well Shuttle™ system, 96-well Nucleocuvette™ plates and modules , HT Nucleofector™ and 384-well Nucleocuvette™ plates is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH. Amata, Nucleofector, Nucleofection and maxGFP are either registered trademarks or trademarks of the Lonza Cologne GmbH in Germany and/or U.S. and/or other countries. Falcon is a trademark of BD Biosciences. TallTips are a registered trademark of Matrix Technologies Corporation. ATCC® and the ATCC Catalog Marks are trademarks of ATCC. Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com. The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242. The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license. No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2011, Lonza Cologne GmbH. All rights reserved—D5SP-9011 2011-10